Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

462.99 -7.88 (-1.67%)
Streaming Delayed Price Updated: 3:58 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
News headline image
2 Inflation-Proof Growth Stocks That Could Outperform the Market ↗
Inflation should have a minimal impact on these companies' financial results. And they also boast excellent growth prospects. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors ↗
Vertex Pharmaceuticals (VRTX) presents a strong value investment case with a low P/E ratio, robust profitability, a healthy debt-free balance sheet, and accelerating earnings growth. 
Via Chartmill
News headline image
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of... 
Via MarketMinute
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
These stocks both have advanced in the double-digits in recent months. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November ↗
It's a good idea to go against the current market sentiment on this one. 
Via The Motley Fool
News headline image
The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market
The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top Affordable Growth Stock ↗
Vertex Pharmaceuticals offers strong growth, solid profits, and a healthy balance sheet, all at a reasonable valuation compared to its biotech peers. 
Via Chartmill
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment.... 
Via StockStory
Topics Earnings
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Global Markets Brace for Inflation's Enduring Grip: A November 2025 Outlook
As November 2025 unfolds, global financial markets find themselves in a complex and challenging environment, bracing for the enduring grip of inflation. Despite some signs of moderating headline... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs. 
Via Benzinga
News headline image
2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that... 
Via StockStory
News headline image
Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday? ↗
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date... 
Via Benzinga
News headline image
VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was... 
Via StockStory
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was... 
Via StockStory
News headline image
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book ↗
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost. 
Via Investor's Business Daily
News headline image
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon ↗
These healthcare stocks are making strides in very important ways. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Nvidia, Amazon Extend Rally, Bitcoin Sinks To $107,000: What's Moving Markets Monday? ↗
Wall Street opened the week on a mixed note on Monday. 
Via Benzinga
News headline image
Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years? ↗
These are great picks with or without soaring inflation. 
Via The Motley Fool
Topics Economy Government World Trade
News headline image
My Top Growth Stock to Buy in November ↗
This stock isn't bulletproof. But it should be a big winner over the coming years. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know. 
Via StockStory
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.